1Ohki Y, Kato M, Kimura H, et al. Elevated type Ⅳ collagen in bronchoalveolar lavage fluid from infants with bronchopulmonary dysplasia. Biol Neonate, 2001,79:34-38.
2Sinkin RA, Roberts M, LoMonaeo MB, et al. Fibroneetin expression in bronchopulmonary dysplasia.Pediatr Dev Pathol,1998,1:494-502.
3Cherukupalli K, Larson JE, Rotschild A, et al. Biochemical,clinical, and morphologic studies on lungs of infants with bronchopulmonary dysplasia. Pediatr Pulmonol,1996,22:215-229.
4Singhal KK, Parton LA. Plasminogen activator activity in preterm infants with respiratory distress syndrome: relationship to the development of bronchopulmonary dysplasia. Pediatr Res,1996,39:229-235.
5Eitzman DT, McCoy RD, Zheng X, et al. Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene. J Clin Invest,1996,97:232-237.
6Hattori N, Degen JL, Sisson TH, et al. Bleomycin-induced pulmonary fibrosis in fibrinogen-null mice. J Clin Invest, 2000,106:1341-1350.
7Sisson TH, Hattori N, Xu Y, et al. Treatment of bleomycin-induced pulmonary fibrosis by transfer of urokinase-type plasminogen activator genes. Hum Gene Ther, 1999,10:2315-2323.
8Hart DA, Whidden P, Green F, et al. Partial reversal of established bleomycin-induced pulmonary fibrosis by rh-urokinase in a rat model. Clin Invest Med, 1994,17:69-76.
9Sisson TH, Hanson KE, Subbotina N, et al. Inducible lung-specific urokinase expression reduces fibrosis and mortality after lung injury in mice. Am J Physiol Lung Cell Mol Physiol,2002,283:L1023-1032.
10Cederqvist K, Sorsa T, Tervahartiala T, et al. Matrix metallo-proteinases-2, 8, and -9 and TIMP-2 in tracheal aspirates from preterm infants with respiratory distress. Pediatrics, 2001,108: 686-692.
